ML290 | CAS#1482500-76-4 |RXFP1 Agonist

ML290
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 533244

CAS#: 1482500-76-4

Description: ML290 is a potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1).

Chemical Structure

ML290

CAS# 1482500-76-4

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 533244
Name: ML290
CAS#: 1482500-76-4
Chemical Formula: C24H21F3N2O5S
Exact Mass: 506.11
Molecular Weight: 506.496
Elemental Analysis: C, 56.91; H, 4.18; F, 11.25; N, 5.53; O, 15.79; S, 6.33

Price and Availability

Size	Price	Availability
5mg	USD 350	2 Weeks
25mg	USD 850	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: ML290; ML 290; ML-290.

IUPAC/Chemical Name: 2-[(2-propan-2-yloxybenzoyl)amino]-N-[3-(trifluoromethylsulfonyl)phenyl]benzamide

InChi Key: RSYHJSDOGMSLDH-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H21F3N2O5S/c1-15(2)34-21-13-6-4-11-19(21)23(31)29-20-12-5-3-10-18(20)22(30)28-16-8-7-9-17(14-16)35(32,33)24(25,26)27/h3-15H,1-2H3,(H,28,30)(H,29,31)

SMILES Code: O=C(NC1=CC=CC(S(=O)(C(F)(F)F)=O)=C1)C2=CC=CC=C2NC(C3=CC=CC=C3OC(C)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	ML-290 is a relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.
In vitro activity:	Therefore, this study has tested the effect of ML290 on primary human HSC gene expression (Figure 3). Cells were cultured on plastic, which induces and maintains activation of HSCs. Upon treatment with 5μM of ML290, this study observed a clear anti-fibrotic, relaxin-like gene expression pattern at 24 and 72 hr. Similar results have been recently reported by another group in the HSC LX-2 cell line using ML-290. Reference: Eur J Med Chem. 2018 Aug 5;156:79-92. https://pubmed.ncbi.nlm.nih.gov/30006176/
In vivo activity:	The pharmacokinetics of ML290 in mice demonstrated its high stability in vivo, as evidenced by the sustained concentrations of compound in the liver. In mice expressing human RXFP1 gene treated with carbon tetrachloride, ML290 significantly reduced collagen content, α-smooth muscle actin expression, and cell proliferation around portal ducts. In conclusion, ML290 demonstrated antifibrotic effects in liver fibrosis. Reference: FASEB J. 2019 Nov;33(11):12435-12446. https://pubmed.ncbi.nlm.nih.gov/31419161/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	30.0	59.23
	DMF:PBS (pH 7.2) (1:2)	0.3	0.65
	DMSO	75.0	148.08
	Ethanol	0.1	0.28

Preparing Stock Solutions

The following data is based on the product molecular weight 506.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Wilson KJ, Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer M, Southall N, Hu X, Zheng W, Xu X, Wang A, Myhr C, Barnaeva E, George ER, Agoulnik AI, Marugan JJ. Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. Eur J Med Chem. 2018 Aug 5;156:79-92. doi: 10.1016/j.ejmech.2018.06.008. Epub 2018 Jun 7. PMID: 30006176; PMCID: PMC6102074. 2. Kocan M, Sarwar M, Ang SY, Xiao J, Marugan JJ, Hossain MA, Wang C, Hutchinson DS, Samuel CS, Agoulnik AI, Bathgate RAD, Summers RJ. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1. Sci Rep. 2017 Jun 7;7(1):2968. doi: 10.1038/s41598-017-02916-5. PMID: 28592882; PMCID: PMC5462828. 3. Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Devarasetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J. 2019 Nov;33(11):12435-12446. doi: 10.1096/fj.201901046R. Epub 2019 Aug 16. PMID: 31419161; PMCID: PMC6988856. 4. Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. PMID: 26347712; PMCID: PMC4538381.
In vitro protocol:	1. Wilson KJ, Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer M, Southall N, Hu X, Zheng W, Xu X, Wang A, Myhr C, Barnaeva E, George ER, Agoulnik AI, Marugan JJ. Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. Eur J Med Chem. 2018 Aug 5;156:79-92. doi: 10.1016/j.ejmech.2018.06.008. Epub 2018 Jun 7. PMID: 30006176; PMCID: PMC6102074. 2. Kocan M, Sarwar M, Ang SY, Xiao J, Marugan JJ, Hossain MA, Wang C, Hutchinson DS, Samuel CS, Agoulnik AI, Bathgate RAD, Summers RJ. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1. Sci Rep. 2017 Jun 7;7(1):2968. doi: 10.1038/s41598-017-02916-5. PMID: 28592882; PMCID: PMC5462828.
In vivo protocol:	1. Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Devarasetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J. 2019 Nov;33(11):12435-12446. doi: 10.1096/fj.201901046R. Epub 2019 Aug 16. PMID: 31419161; PMCID: PMC6988856. 2. Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. PMID: 26347712; PMCID: PMC4538381.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Agoulnik AI, Agoulnik IU, Hu X, Marugan J. Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1. Br J Pharmacol. 2016 Oct 23. doi: 10.1111/bph.13656. [Epub ahead of print] Review. PubMed PMID: 27771940.

2: Hu X, Myhr C, Huang Z, Xiao J, Barnaeva E, Ho BA, Agoulnik IU, Ferrer M, Marugan JJ, Southall N, Agoulnik AI. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry. 2016 Mar 29;55(12):1772-83. doi: 10.1021/acs.biochem.5b01195. PubMed PMID: 26866459; PubMed Central PMCID: PMC5137375.

3: Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. PubMed PMID: 26347712; PubMed Central PMCID: PMC4538381.

4: Halls ML, Bathgate RA, Sutton SW, Dschietzig TB, Summers RJ. International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol Rev. 2015;67(2):389-440. doi: 10.1124/pr.114.009472. Review. PubMed PMID: 25761609; PubMed Central PMCID: PMC4394689.

5: Diepenhorst NA, Petrie EJ, Chen CZ, Wang A, Hossain MA, Bathgate RA, Gooley PR. Investigation of interactions at the extracellular loops of the relaxin family peptide receptor 1 (RXFP1). J Biol Chem. 2014 Dec 12;289(50):34938-52. doi: 10.1074/jbc.M114.600882. PubMed PMID: 25352603; PubMed Central PMCID: PMC4263891.

6: Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer M, Southall N, Hu X, Zheng W, Agoulnik AI, Marugan JJ. Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1). 2012 Mar 10 [updated 2013 May 8]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK153218/ PubMed PMID: 23905199.

Your view history

ML290 featured